Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 21, 2008, Pages 6740-6751

  Santana, Lourdes ^a   González Díaz, Humberto ^a   Quezada, Elías ^a   Uriarte, Eugenio ^a   Yáñez, Matilde ^a   Viña, Dolores ^a   Orallo, Francisco ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 BENZO 7 (B BROMOALLYLOXY) 8 METHYLCOUMARIN; 3,4 BENZO 7 ACETONYLOXY 8 METHOXYCOUMARIN; 3,4 BENZO 7 ACETONYLOXY 8 METHYLCOUMARIN; 4'5' CYCLOHEXENE 4,8 DIMETHYLFURO[3,2 G]COUMARIN; 4'5' CYCLOPENTENE 4,8 DIMETHYLFURO[3,2 G]COUMARIN; 4,8 DIMETHYL 7 (2' OXOCYCLOHEXYLOXY)COUMARIN; 4,8 DIMETHYL 7 (2' OXOCYCLOPENTYLOXY)COUMARIN; 5 METHOXY 4' METHYLFURO[3,2 G]COUMARIN; 7 (BETA BROMOALLYLOXY) 3,4 CYCLOHEXENE 8 METHYLCOUMARIN; 7 (BETA BROMOALLYLOXY) 3,4 CYCLOPENTENE 8 METHYLCOUMARIN; 7 ACETONYLOXY 3,4 CYCLOHEXENE 8 METHYLCOUMARIN; 7 ACETONYLOXY 3,4 CYCLOPENTENE 8 METHYLCOUMARIN; 7 ACETONYLOXY 5 METHOXYCOUMARIN; 8 METHOXY 4 METHYL 7 (2' OXOCYCLOPENTYLOXY)COUMARIN; 8 METHYL 3,4 CYCLOHEXENE 7 HYDROXYCOUMARIN; 8 METHYL 3,4 CYCLOPENTENE 7 HYDROXYCOUMARIN; CLORGYLINE; COUMARIN DERIVATIVE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; SELEGILINE; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INHIBITION; EXPERIMENTAL STUDY; HUMAN; IC 50; MODEL; MOUSE; NONHUMAN; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THEORETICAL STUDY;

COMPUTATIONAL BIOLOGY; DRUG DESIGN; HUMANS; ISOENZYMES; MOLECULAR STRUCTURE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 56249083925     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800656v     Document Type: Article

References (52)

1. Dostert, P.; Strolin Benedetti, M.; Jafre, M. Structural modifications in oxazolidinone series leading to type A or B selective monoamine oxidase inhibitors. In Monoamine Oxidase: Basic and Clinical Frontiers; Kamijo, K., Usdin, E., Nagausu, T., Eds.; Excerpta Medica: Amsterdam, 1982; pp 197-208.
2. Singer, T. P. Monoamine oxidases. In Chemistry and Biochemistry of Flauoenzymes (II); Muller, F., Ed.; CRC Press: London, 1991; pp 437-470.
3. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl. Acad. Sci. U.S.A. 2005, 102, 12684-12689.
4. Binda, C.; Li, M.; Hubálek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 9750-9755.
5. Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004, 25, 11-20.
6. Rudorfer, M. V.; Potter, V. Z. Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the "newer" versus the "older" drugs. Drugs 1989, 37, 713-738.
7. Palhagen, S.; Heinonen, E.; Hagglund, J.; Kaugesaar, T.; Maki-Ikola, O.; Palm, R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006, 66, 1200-1206.
8. Guay, D. R. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am. J. Geriatr. Pharmacother. 2006, 4, 330-346.
9. Riederer, P.; Danielczyk, W.; Grunblatt, E. Monoamine oxidase-B inhibition in Alzheimer's desease. Neurotoxicology 2004, 25, 271-277.
10. Youdim, M. B. H.; Fridkin, M.; Zheng, H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J. Neural Transm. 2004, 111, 1455-1471.
11. Cesura, A. M.; Pletscher, A. The new generation of monoamine oxidase inhibitors. Prog. Drug Res. 1992, 38, 171-297.
12. Youdim, M. B. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction. Acta Psychiatr. Scand., Suppl. 1995, 386, 5-7.
13. Edmondson, D. E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F. Structure and mechanism of monoamine oxidase. Curr. Med. Chem. 2004, 11, 1983-1993.
14. Tipton, K. F.; Boyce, S.; O'Sullivan, J.; Davey, G. P.; Healy, J. Monoamine oxidases: Certainties and uncertainties. Curr. Med. Chem. 2004, 11, 1965-1982.
15. Edmondson, D. E.; Binda, C.; Mattevi, A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch Biochem. Biophys. 2007, 464, 269-276.
16. Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D. E.; Mattevi, A. Crystal Structures of Monoamine Oxidase B in Complex with Four Inhibitors of the N-Propargylaminoiniane Class. J. Med. Chem. 2004, 47, 1767-1774.
17. Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F.; Cirilli, R.; La Torre, F.; Cardia, M. C.; Distinto, S. Synthesis, Molecular Modeling Studies, and Selective Inhibitory Activity against Monoamine Oxidase of 1-Thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)-pyrazole Derivatives. J. Med. Chem. 2005, 48, 7113-7122.
18. Harkcom, W. T.; Bevan, D. R. Molecular docking of inhibitors into monoamine oxidase B. Biochem. Biophys. Res. Commun. 2007, 360, 401-406.
19. Gallardo-Godoy, A.; Fierro, A.; McLean, T. H.; Castillo, M.; Cassels, B. K.; Reyes-Parada, M.; Nichols, D. E. Sulfur-Substituted α-Alkyl Phenethylamines as Selective and Reversible MAO-A Inhibitors: Biological Activities, CoMFA Analysis, and Active Site Modeling. J. Med. Chem. 2005, 48, 2407-2419.
20. Mevedev, A. E.; Veselovsky, A. V.; Shvedov, V. I.; Tikhonova, T. A.; Moskvitinia, T. A.; Fedotova, O. A.; Axenova, L. N.; Kamyshanskaya, A. Z.; Kirkel, A. Z.; Ivanov, A. Inhibition of Monoamino Oxidase by Pirlindole Analogues: 3D-QSAR and CoMFA Analysis. J. Chem. Inf. Comput. Sci. 1998, 38, 1137-1144.
21. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Cirilli, R.; La Torre, F.; Alcaro, S.; Ortuso, F.; Langer, T. Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted- 4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors. Curr. Med. Chem. 2006, 13, 1411-1428.
22. Gnerre, C.; Catto, M.; Francesco, L.; Weber, P.; Carrupt, P.-A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of Monoamine Oxidase by Functionalized Coumarin derivatives: Biological Activities, QSAR, and 3D-QSARs. J. Med. Chem. 2000, 43, 4747-4758.
23. Nunez, M. B.; Maguna, F. P.; Okulik, N. B.; Castro, E. A. QSAR modeling of the MAO inhibitory activity of xanthone derivatives. Bioorg. Med. Chem. Lett. 2004, 14, 5611-5617.
24. Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors; Mannhold, R., Kubinyi, H., Timmerman, H., Eds.; Wiley-VCH: Weinheim, 2000.
25. Kier, L. B.; Hall, L. H. The Kappa indices for modeling molecular shape and flexibility in Topological Indices and Related Descriptors in QSAR and QSPR; Devillers, J., Balaban, A. T., Eds.; Gordon and Breach Science Publishers: Amsterdam, 1999, pp 445-489.
26. Estrada, E.; Uriarte, E.; Montero, A.; Teijeira, M.; Santana, L.; De Clercq, E. A Novel Approach for the Virtual Screening and Rational Design of Anticancer Compounds. J. Med. Chem. 2000, 43, 1975-1985.
27. Erdem, S. S.; Karahan, O.; Yildiz, I.; Yelekci, K. A computational study on the amine-oxidation mechanism of monoamine oxidase: insight into the polar nucleophilic mechanism. Chem. Org. Biomed. Chem. 2006, 4, 646-658.
28. Freund, J. A., Poschel, T. Eds. Stochastic Processes in Physics, Chemistry, and Biology. In Lecture Notes in Physics; Springer-Verlag: Berlin, Germany, 2000.
29. González-Díaz, H.; Agüero, G.; Cabrera, M. A.; Molina, R.; Santana, L.; Uriarte, E.; Delogu, G.; Castanedo, N. Unified Markov thermodynamics based on stochastic forms to classify drugs considering molecular structure, partition system, and biologic species. Distribution of the antimicrobial G1 on rat tissues. Bioorg. Med. Chem. Lett. 2005, 15, 551-557.
30. González-Díaz, H.; Cruz-Monteagudo, M.; Molina, R.; Tenorio, E.; Uriarte, E. Predicting multiple drugs side effects with a general drug - target interaction thermodynamic Markov model. Bioorg. Med. Chem. 2005, 13, 1119-1129.
31. González-Díaz, H.; Torres-Gómez, L. A.; Guevara, Y.; Almeida, M. S.; Molina, R.; Castañedo, N.; Santana, L.; Uriarte, E. Markovian chemicals "in silico" design (MARCH-INSIDE), a promising approach for computer-aided molecular design III: 2.5D indices for the discovery of antibacterials. J. Mol. Model. 2005, 11, 116-123.
32. Santana, L.; Uriarte, E.; González-Díaz, H.; Zagotto, G.; Soto-Otero, R.; Méndez-Alvarez, E. A QSAR Model for in Silico Screening of MAO-A Inhibitors. Prediction, Synthesis, and Biological Assay of Novel Coumarins. J. Med. Chem. 2006, 49, 1149-1156.
33. Fierro, A.; Osorio-Olivares, M.; Cassels, K.; Edmondson, D. E.; Sepulveda-Boza, S.; Reyes-Parada, M. Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylfhioamphetamine derivatives: insights from molecular modeling studies. Bioorg. Med. Chem. 2007, 15, 5198-5206.
34. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Leonetti, F.; Catto, M.; Carrupt, P. A.; Reist, M. Impact of Species-Dependent Differences on Screening, Design, and Development of MAO-B Inhibitors. J. Med. Chem. 2006, 49, 6264-6272.
35. Van Waterbeemd, H. Discriminant analysis for activity prediction. In Chemometric Methods in Molecular Design. Method and Principles in Medicinal Chemistry, Vol. 2; Wiley-VCH: Weinhiem, 1995; pp 265-282.
36. Kleeman, A.; Engel, J.; Kutscher, B.; Reichert, D. Pharmaceutical Substances: Syntheses, Patents and Applications, 4th Ed.; George Thieme Verlag: Stuttgart, 2001.
37. Negwer, M. Organic Chemical Drugs and their Synonyms: An International Survey; Akademie-Verlag: Berlin, 1987.
38. Iding, H.; Jolidon, S.; Krummenacher, D.; Rodriguez Sarmiento, R. M.; Thomas, A. W.; Wirz, B.; Wostl, W.; Wyler, R. (F. Hoffmann-La Roche A.-G., Switzerland). Preparation of arylpyrrolidones as monoamine oxidase-B (MAO-B) inhibitors. Patent WO 2004026825 A1, 2004.
39. Jolidon, S.; Rodriguez-Sarmiento, R. M.; Thomas, A. W.; Wostl, W.; Wyler, R. (F. Hoffmann-La Roche A.-G., Switzerland). Preparation of 4-pyrrolidinophenyl benzyl ether derivatives as monoamine oxidase B inhibitors. Patent WO 2004026826 A1, 2004.
40. Borges, F.; Roleira, F.; Mihazes, N.; Santana, L.; Uriarte, E. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr. Med. Chem, 2005, 12, 887-916.
41. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F. Inhibition of monoamine oxidases by coumarin-3-acyl derivatives: biological activity and computational study. Bioorg. Med. Chem. Lett. 2004, 14, 3697-3703.
42. Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Soto-Otero, R.; Mendez-Alvarez, E.; Carotti, A. Structural Insights into Monoamine Oxidase Inhibitory Potency and Selectivity of 7-Substituted Coumarins from Ligand- and Target-Based Approaches. J. Med. Chem. 2006, 49, 4912-4925.
43. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D. E.; Mattevi, A. Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: Safinamide and Coumarin Analogs. J. Med. Chem. 2007, 50, 5848-5852.
44. Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; Summo, L.; De Marco, A.; Rose, S.; Jenner, P.; Testa, B. Lipophilicity Plays a Major Role in Modulating the Inhibition of Monoamine Oxidase B by 7-Substituted Coumarins. Chem. Biodiversity 2006, 3, 134-149.
45. Dalla Via, L.; Uriarte, E.; Quezada, E.; Dolmella, A. M. G.; Ferlin, M. G.; Gia, O. Novel Pyrone Side Tetracyclic Psoralen Derivatives: Synthesis and Photobiological Activity. J. Med. Chem. 2003, 46, 3800-3810.
46. Gia, O.; Marciani-Magno, S.; González-Díaz, H.; Quezada, E.; Santana, L.; Uriarte, E.; Dalla Via, L. Design, Synthesis and Photobiological Properties of 3,4-Cyclopentene Psoralens. Bioorg. Med. Chem. 2005, 13, 809-817.
47. Dalla Via, L.; Uriarte, E.; Santana, L.; Marciani-Magno, S.; Gia, O. Methyl derivatives of tetracyclic psoralen analogues: antiproliferative activity and interaction with DNA. ARKIVOC 2004, 5, 131-146.
48. Yáñez, M.; Fraiz, N.; Cano, E.; Orallo, F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem. Biophys. Res. Commun. 2006, 344, 688-695.
49. González-Díaz, H.; Molina-Ruiz, R.; Hernandez, I. MARCH-INSIDE (MARkov CHains IN variants for Simulation & DEsign), version 3.0. Windows supported version released under request to the main author. Contact E-mail: humberto.gonzalez@usc.es.
50. Statistica Software, version 8.0; StatSoft Iberica Portugal Lda.: Lisboa, Portugal, 2008.
51. Junker, B. H.; Koschützki, D.; Schreiber, F. Exploration of biological network centralities with CentiBiN. BMC Bioinform. 2006, 7, 219.
52. Batagelj, V.; Mrvar, A. Pajek: Program for Large Network Analysis. Home page: http://vlado.fmf.uni-lj.si/pub/networks/pajek/.